SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Stefan Schreiber  ¹     Severine Vermeire  ²     David T. Rubin  ³     Silvio Danese  ^{4, 5}     Rajiv Mehta  ⁶     Xavier Roblin  ⁷     Paul Kwon  ⁸     Paul van Hoek  ⁹     Tomasz Masior  ¹⁰     Rahul Barron     Franck-Olivier Le Brun     Mamoru Watanabe  ^11    
1 University Hospital Schleswig-Holstein, Kiel, Germany
² UZ Leuven, Leuven, Belgium
³ University of Chicago Medicine, Chicago, United States
⁴ IRCCS Hospital San Raffaele, Milan, Italy
⁵ Vita-Salute San Raffaele University, Milan, Italy
⁶ Surat Institute of Digestive Sciences Hospital, Surat, India
⁷ University Hospital of Saint-Étienne, Saint-Étienne, France
⁸ Gilead Sciences Inc., Foster City, United States
⁹ Galapagos NV, Mechelen, Belgium
¹⁰ Galapagos GmbH, Basel, Switzerland
¹¹ Tokyo Medical and Dental University, Tokyo, Japan

Topic
IBD

Session
Medical therapy of IBD: Facts and challenges (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)